File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The effectiveness and safety of intrauterine infusion of autologous regulatory T cells (Tregs) in patients with recurrent pregnancy loss and low levels of endometrial FoxP3+ cells: A retrospective cohort study

TitleThe effectiveness and safety of intrauterine infusion of autologous regulatory T cells (Tregs) in patients with recurrent pregnancy loss and low levels of endometrial FoxP3+ cells: A retrospective cohort study
Authors
KeywordsEndometrial receptivity
Intrauterine infusion
Maternal–fetal immunomodulatory
Recurrent pregnancy loss
Regulatory T cells
Issue Date20-Jun-2023
PublisherAmerican Society for Reproductive Immunology
Citation
American Journal of Reproductive Immunology, 2023, v. 90, n. 2 How to Cite?
Abstract

Problem

Regulatory T cells (Tregs) are a specialized type of T cells that help maintain immune tolerance and homeostasis. The potential of Tregs cell-based therapies in treating diseases has been demonstrated in several clinical trials, which have shown promising outcomes and high safety in autoimmune diseases, transplant rejection, and graft-versus-host disease. However, their effectiveness and safety in improving endometrial receptivity and reducing pregnancy loss in human reproduction are unknown.

Method of study

The study used a retrospective design and included patients with recurrent pregnancy loss (RPL) and lower levels of endometrial FoxP3+ Tregs. Patients in the Tregs group (n = 33) received intrauterine Tregs infusion three times during the follicular phase, while the control group (n = 28) did not receive any intrauterine infusion.

Results

The intrauterine infusion of autologous Tregs increased the levels of FoxP3+ Tregs and CD56+ NK cells. Patients in the Treg group had higher live birth rates and lower miscarriage rates, especially early miscarriage rates. However, the two groups had no differences in the implantation rate, clinical pregnancy rate, and percentage of preterm delivery.

Conclusions

The findings suggest that intrauterine Tregs infusion may be a potential therapeutic approach for RPL. Further research in larger clinical trials is needed to confirm these findings.


Persistent Identifierhttp://hdl.handle.net/10722/329211
ISSN
2023 Impact Factor: 2.5
2023 SCImago Journal Rankings: 0.887
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCai, Songchen-
dc.contributor.authorDai, Su-
dc.contributor.authorLin, Rong-
dc.contributor.authorHuang, Chunyu-
dc.contributor.authorZeng, Yong-
dc.contributor.authorDiao, Lianghui-
dc.contributor.authorLian, Ruochun-
dc.contributor.authorTu, Wenwei-
dc.date.accessioned2023-08-05T07:56:08Z-
dc.date.available2023-08-05T07:56:08Z-
dc.date.issued2023-06-20-
dc.identifier.citationAmerican Journal of Reproductive Immunology, 2023, v. 90, n. 2-
dc.identifier.issn1046-7408-
dc.identifier.urihttp://hdl.handle.net/10722/329211-
dc.description.abstract<h3>Problem</h3><p>Regulatory T cells (Tregs) are a specialized type of T cells that help maintain immune tolerance and homeostasis. The potential of Tregs cell-based therapies in treating diseases has been demonstrated in several clinical trials, which have shown promising outcomes and high safety in autoimmune diseases, transplant rejection, and graft-versus-host disease. However, their effectiveness and safety in improving endometrial receptivity and reducing pregnancy loss in human reproduction are unknown.</p><h3>Method of study</h3><p>The study used a retrospective design and included patients with recurrent pregnancy loss (RPL) and lower levels of endometrial FoxP3<sup>+</sup> Tregs. Patients in the Tregs group (<em>n</em> = 33) received intrauterine Tregs infusion three times during the follicular phase, while the control group (<em>n</em> = 28) did not receive any intrauterine infusion.</p><h3>Results</h3><p>The intrauterine infusion of autologous Tregs increased the levels of FoxP3<sup>+</sup> Tregs and CD56<sup>+</sup> NK cells. Patients in the Treg group had higher live birth rates and lower miscarriage rates, especially early miscarriage rates. However, the two groups had no differences in the implantation rate, clinical pregnancy rate, and percentage of preterm delivery.</p><h3>Conclusions</h3><p>The findings suggest that intrauterine Tregs infusion may be a potential therapeutic approach for RPL. Further research in larger clinical trials is needed to confirm these findings.</p>-
dc.languageeng-
dc.publisherAmerican Society for Reproductive Immunology-
dc.relation.ispartofAmerican Journal of Reproductive Immunology-
dc.subjectEndometrial receptivity-
dc.subjectIntrauterine infusion-
dc.subjectMaternal–fetal immunomodulatory-
dc.subjectRecurrent pregnancy loss-
dc.subjectRegulatory T cells-
dc.titleThe effectiveness and safety of intrauterine infusion of autologous regulatory T cells (Tregs) in patients with recurrent pregnancy loss and low levels of endometrial FoxP3+ cells: A retrospective cohort study-
dc.typeArticle-
dc.identifier.doi10.1111/aji.13735-
dc.identifier.scopuseid_2-s2.0-85162856773-
dc.identifier.volume90-
dc.identifier.issue2-
dc.identifier.eissn1600-0897-
dc.identifier.isiWOS:001036824500008-
dc.identifier.issnl1046-7408-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats